相关实验视频
Updated: Feb 26, 2026

06:15
Preparation of Binary and Ternary Deep Eutectic Systems
Published on: October 31, 2019
12.8K
作为使制药配方成为可能的深层欧特克系统:机制和应用
Shaida Panbachi1, Josef Beránek2, Martin Kuentz3
1University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.
概括
深度体系统 (DES) 增强药物溶解性,改善口服生物可用性并减少对环境的影响. 这些新型配方为开发易溶性药物化合物提供了可持续的解决方案.
科学领域:
- 制药科学 制药科学
- 绿色化学 绿色化学
- 化学工程是化学工程的重要组成部分.
背景情况:
- 由于水溶性差,许多新的制药化合物在开发中失败.
- 深度欧特克系统 (DES) 正在成为药物中可溶性增强的有前途的解决方案.
研究的目的:
- 介绍DES及其与类似系统相比的性能.
- 对于配方应用来说,重新审视优化剂,DES和治疗性DES (THEDES).
- 概述对DES属性的计算研究,如溶解性和毒性.
主要方法:
- 关于DES在制药中的应用的文献综述.
- 对DES与其他多元件系统进行比较分析.
- 用于研究DES属性的计算技术的概述.
主要成果:
- 对于不易溶解的化合物,DES是有效的溶解剂.
- 可以使用DES作为药物配方的启用配方.
- 计算研究提供了关于DES可溶性和毒性的见解.
结论:
- 液体DES为可溶性促进配方提供了可行的策略.
- 由DES增加的口服生物可用性提高了生物制药的性能,并减少了API浪费.
- DES应用在制药开发中呈现了一种可持续的方法.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
663
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
663
Bioavailability Enhancement: Drug Permeability Enhancement
266
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
266
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
208
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
208
Modified-Release Drug Delivery Systems: Overview
53
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
53
Drug Delivery Systems: Different Types
92
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
92
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
613
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
613

